Long-term Efficacy Observation of Recombinant Bone Xenograft in Treatment of Nonunion

YU Zhong-ying,YUAN Zhi,ZHANG Wei,LI Yan,CHEN Zhao,MA Zhi-jun,YU Yuan
DOI: https://doi.org/10.3969/j.issn.1671-1815.2012.25.006
2012-01-01
Abstract:To evaluate long-term efficacy of recombinant bone xenograft in treatment of nonunion,62 patients suffered with femoral non-infected nonunion from 2000-1 to 2006-9 was analyzed retrospectively,which included 52 males and 10 females,with the mean age of 30.1 years(ranged from 4 to 70 years).The nonunion site:radius and ulna in 11 cases,humerus 9 cases,tTibia and fibula 22cases,and 20 cases of femur.There were 15 hypertrophic cases,10 malnourished and 37 atrophic.21 cases with plate,19 cases with intramedullary nailing and 22 cases with external fixation.It is resulted that average follow-up time of these cases was 89.3 months,from 50 months to 131 months.94.9% of these patients healed with only one operation.Using DASH scale to assessment the function of 19 upper limb cases,excellent in 13,good in 5 and 1 fair,with an excellent to good rate of 94.7%.43 lower limb cases were scaled with the American Knee Society Score(KSS)and Harris,the function was rated as excellent in 26,good in 15 and fair in 2,with an excellent to good rate of 95.3%.The total excellent to good rate was 95.2%.No one has immune rejection in this long-term observation.It is conlused that RBX for the treatment of nonunion has many advantages,such as sufficient materia,a nice biological compatibility,it can be used in the clinic instead of autologous bone.
What problem does this paper attempt to address?